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INTRODUCTION
Rotavirus is the leading cause of acute gastroenteritis in in-
fants and young children. It causes severe diarrhea and can 
lead to dehydration. Globally, it causes more than a half mil-
lion deaths each year in children younger than five years. Also, 
it leads to two million hospitalizations and 25 million outpa-
tient visits among children younger than five years world-
wide.1,2 Despite improvements in sanitation and hygiene, the 
incidence of rotavirus gastroenteritis has not markedly de-
creased, even in developed countries. This is the reason for the 
development of the rotavirus vaccine.
In August 1998, the RotaShield® (Wyeth, Delaware Valley, 
PA, USA) vaccine was first approved to prevent rotavirus gas-
troenteritis. Soon after its introduction, the risk of intussuscep-
tion (IS) increased 20 to 30 times over the expected risk for 
children of this age group within two weeks following their first 
dose of the RotaShield® vaccine.3-6 Based on the results of in-
vestigations, the US Centers for Disease Control and Prevention 
estimated that one or two additional cases of IS would be caused 
among each 10000 infants vaccinated with the RotaShield® vac-
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Purpose: Despite withdrawal of RotaShield® and the development of second generation live attenuated rotavirus vaccines, con-
cerns remain regarding the relationship between rotavirus vaccine and intussusception. Nevertheless, since there is no study in 
Korea, we reviewed data from cases at Severance Children’s Hospital to determine the association between rotavirus vaccine and 
intussusception.
Materials and Methods: Patients coded as intussusception and following a prescription of RotaTeq® from 2007 to 2013 were re-
viewed. We calculated comparative incidence figures (CIFs) and 95% confidence intervals (CIs) to compare the risk of intussus-
ception in Korea with the risk in the United States. Expected cases within the four-week post-vaccination window were calculated 
by applying rates of intussusception from data compiled by the Health Insurance Review and Assessment Service (for a five-year 
period) to numbers of vaccinations.
Results: In total, 10530 doses of pentavalent rotavirus vaccine were administered. A total of 65 intussusception cases were diag-
nosed, although only two cases occurred within four weeks after vaccination. This was compared to six cases within 999123 doses 
in United States from April 2008 to March 2013 (CIF, 31.63; CI, 31.33–31.93). When we adjusted incidence rate differences for both 
countries, the CIF decreased to 7.05 (CI, 6.72–7.40). When we compared our identified cases with the expected cases from our hospi-
tal, there was no increased intussusception occurring within four weeks of vaccination.
Conclusion: We found no association between pentavalent rotavirus vaccine and intussusception. Therefore, rotavirus vaccina-
tion should be considered due to its benefits of preventing rotavirus-associated diseases.
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cine. In October 1999, RotaShield® was withdrawn from the 
market.
RotaTeq® (Merck, West Point, PA, USA), a pentavalent rota-
virus vaccine, and Rotarix®, a monovalent rotavirus vaccine, 
were licensed in the United States in 2006 and 2008, respec-
tively.7,8 Because of the previous association between rotavirus 
vaccination and IS, large studies were done before licensing. 
No increased risk was found for IS after each vaccine.9,10 In 
2009, rotavirus vaccination was recommended by the World 
Health Organization for all infants.11 Post-licensure studies of 
the association between vaccine and IS have been published 
in the United States, Australia, and Latin America. Studies from 
Australia, Brazil, and Mexico and one of three studies from 
United States have found an increased risk of IS.10,12-19 
In Korea, a recent study has estimated the incidence of rota-
virus-related gastroenteritis in children less than five years old 
to be 56.9 cases/1000 children.20 Rotavirus gastroenteritis rarely 
causes mortality, although it causes significant morbidity in 
Korea. In Korea, RotaTeq® and Rotarix® were first used in 2007 
and 2008, respectively. Even though it has not been included 
in the National Immunization Program (NIP), the rate of rota-
virus vaccination has been increasing consistently, and in 2010, 
the rate had reached 60.8%. However, no studies have been 
conducted in Korea that prove or disprove the association be-
tween rotavirus vaccination and IS. The aim of this study was to 
evaluate the association between the rotavirus vaccine and IS 
in Korea. 
MATERIALS AND METHODS
We reviewed the medical records of children below 12 months 
of age who the visited the outpatient clinic and emergency room 
of Severance Children’s Hospital from January 1, 2005, to De-
cember 31, 2013. Confirmed IS cases were identified retro-
spectively by searching hospital databases using ICD-9-CM 
codes. Each case was confirmed with ultrasonography by an 
expert radiologist. We collected information regarding the vac-
cination schedule of all patients. As our hospital started to use 
only pentavalent rotavirus vaccine in November 2007, we an-
alyzed the data of the RotaTeq® vaccine only. We defined the 
risk window to constitute four weeks after the vaccination day, 
because rotavirus vaccination-associated IS is known to occur 
within one month after vaccination, especially following the 
first dose.3
We first compared the pre-vaccination and post-vaccination 
times of patients with IS. The observation period was divided 
into two-month intervals. Standard Poisson-based methods 
were used, and 95% confidence intervals (CIs) were calculated.
Then, we compared our vaccine-associated IS cases in our 
study with those from the United States data, which were part 
of the Vaccine Safety Datalink project.19 We used comparative 
incidence figures (CIFs) and 95% CIs calculated by Byar’s 
method. Based on the difference in the incidence of IS in the 
two compared countries, we adjusted the CIFs accordingly.21,22
Lastly, we compared the observed number of cases with ex-
pected numbers. The relative risk was obtained by dividing the 
number of observed excess by the number of expected cases. 
The number of expected cases of IS in the risk window period 
was calculated by multiplying the child-time at risk post vac-
cination by the estimated background incidence of IS. The 
former was obtained by identifying the number of children 
who had received the RotaTeq® vaccine during the period of 
observation from our hospital’s database. Calculations were 
made separately for each dose of the vaccine. The annual in-
cidence of IS in our hospital was estimated by dividing the 
number of cases of IS by the number of children younger than 
12 months old. 
We calculated the ratio of observed to expected incidence 
(standardized incidence ratio), which provides an estimated 
relative risk under the assumption of constant relative risk. 
Table 1. Total RotaTeq® Doses Administered and Total Infants Vaccinated during the Study Period
2007 2008 2009 2010 2011 2012 2013 Total
Total doses 52 983 1650 1718 1974 2045 2108 10530
Total infants 47 466 644 724 731 781 813 4206
Table 2. Total RotaTeq® Vaccinations Administered and the Number of 
Vaccinations Given One, Two, or Three Doses
Total 10530
Dose 1 4206
Dose 2 3446
Dose 3 2878
Fig. 1. Plot showing a trend for the total infants below 12 months of age 
who visited our hospital (black line), and total diagnosed and treated in-
tussusception infants below 12 months of age in our hospital (gray line) 
between 2005 and 2013. The tendency of intussusception decreased 
across most of the years studied. The reason for the increased number of 
intussusceptions in 2012 remains unclear.
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Standard poisson-based methods were used, which produced 
95% CIs for these relative risks. IBM SPSS statistics, version 20 
(SPSS Inc., Chicago, IL, USA) were used to conduct all the 
analysis.
This study was approved by the Institutional Review Board 
of Severance Hospital, Yonsei University College of Medicine, 
Seoul, Korea (IRB number: 4-2016-0314).
RESULTS
 
From January 1, 2005 to December 31, 2013, a total of 63915 
children below 12 months of age visited our hospital. From 
November 1, 2007 to December 31, 2013, a total of 10530 dos-
es of RotaTeq® vaccine were prescribed to 4206 infants (Tables 
1 and 2). In the same period, 65 cases of IS were identified and 
treated in children below 12 months of age (Fig. 1, Table 3). 
There was a total of 12 cases diagnosed as IS after RotaTeq® 
administration. Ten of these were diagnosed more than four 
weeks after vaccination for rotavirus and could not be defined 
as rotavirus vaccination-associated IS. Two cases were identi-
fied within four weeks of RotaTeq® administration. No cases 
of IS were found after the first dose of RotaTeq® in our hospi-
tal. Both cases were treated by manual reduction. 
When we calculated the incidence over the observation peri-
od, divided into two-month intervals, we observed a periodic 
increase in incidence; however, the overall pattern was a de-
cline in incidents. When we compared the incident rate using 
standard poisson-based methods, a decrease in the risk ratio 
by 0.51 was observed, and there were no increased risks of IS 
on post-vaccination status, compared with pre-vaccination sta-
tus (Fig. 2, Table 4).
Table 3. Number of Total Visited Infants, IS Diagnosed Infants, and IS Diagnosed Infants during Risk Window Period
2005 2006 2007 2008 2009 2010 2011 2012 2013 Total
Total infants 3798 9939 5902 6816 6669 7326 7519 7894 8052 63915
Total infants with IS 11 14 12 8 4 2 3 9 2 65
Total infants with IS
  during the risk window period
- - 0 0 0 0 1 0 1 2
IS, intussusception.
Fig. 2. Number of incidents over the observation period divided into two-month intervals. A periodic increase in incidents is seen; however, the overall 
pattern is a decline in incidence. The incidence rate was calculated using standard poisson-based methods, and a decrease in the risk ratio by 0.51 was 
observed.
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Since there were only two cases of rotavirus vaccination de-
termined among the total cases identified as IS, we compared 
our data with the United States for the same type of rotavirus 
vaccination to identify whether pentavalent rotavirus vaccina-
tion increases the risk of IS (Table 5).19 Compared with the six 
cases among 999123 doses in United States from April 2008 to 
March 2013, the calculated CIF was 31.63 (CI, 31.33–31.93). 
However, after taking into consideration the difference in the 
background incidence rate of IS between the two countries,22 
the incidence rate was determined to be seven times higher in 
Korea than in the US.
Rather than comparing this pattern with that of another coun-
try, we decided to compare these results within our hospital. 
The expected case per vaccination was calculated using the ba-
ckground rate. Based on the assumption that IS is not associ-
ated with rotavirus vaccination, we calculated the relative risk 
and 95% CI (Table 6). The results for our hospital showed that 
the rotavirus vaccine caused no increasing risk of IS.
To aid our understanding of the outcome of this study, we ex-
amined the rotavirus antigen test results from 2005 to 2013 in 
our hospital (Table 7). A decreasing pattern for the rate of pos-
itive rotavirus antigen tests was observed.
DISCUSSION
Generally, natural rotavirus infection is not believed to cause 
IS.23-26 However, the first-developed live oral tetravalent rotavi-
Table 4. Number of Infants Diagnosed with IS at our Facility and the Number of Infants Younger Than 12 Months Who Have Visited Our Facility
2005 2006 2007 2008 2009 2010 2011 2012 2013 Total
IS 34 38 60 45 31 37 44 25 20 334
Infants visiting 3798 9939 5902 6816 6669 7326 7519 7894 8052 63915
IS, intussusception.
Table 5. Results from Our Facility Compared to Those from the VSD Project Conducted in the United States, Which Investigated Pentavalent Vaccine-
Associated IS
United States Severance Hospital
Observed periods (yrs) 4.58 6.17
Total vaccinations 999123 10530
IS new cases 6 2
Calculated crude IS incidence rate (100000 PY) 0.6005267 18.993352
CIF 1 (95% CI) 31.63 (31.33–31.93)
CIF 2 (95% CI) 7.05 (6.72–7.40)
VSD, Vaccine Safety Datalink; IS, intussusception; CIF, comparative incidence figure; CI, confidence interval.
When we used CIFs, the rotavirus vaccine-associated IS rate at our facility was 31.63 times higher than that of the United States report. However, after taking into con-
sideration the difference in the background incidence rate of IS between the two countries, the incidence rate was seven times higher in our hospital. However, one 
thing that needs to be considered here is that our data, which are from a single center study, are smaller compared to the United States data. Also, given that our facility is a 
tertiary medical center, the number of patients diagnosed and treated for IS may be much higher than the number of patients who visit for the sole purpose of receiving 
vaccinations. These factors could have contributed to such discrepancy.
Table 6. Expected Rate per Vaccination Calculated Using the Background Rate 
Doses No. of doses
No. of cases of IS
Relative risk 95% CI
Observed Expected
All doses 10530 2 1.91 1.05 0.12–5.12
Dose 1 4206 0 0.63 -
Dose 2 3446 2 0.62 3.21 0.36–15.65
Dose 3 2878 0 0.52 -
IS, intussusception; CI, confidence interval.
Based on the assumption that IS is not associated with rotavirus vaccination, we calculated the relative risk and 95% CI for the total doses and for those who 
received the second dose. The results indicate that there is no association between the rotavirus vaccination and IS.
Table 7. Examination of the Rotavirus Antigen Test Results from 2005 to 2014 at Our Facility
2005 2006 2007 2008 2009 2010 2011 2012 2013 Total
Rota Ag test 923 1047 1339 1251 1158 921 799 866 669 8973
Rota (+) 149 267 448 268 255 129 108 127 93 1844
Positive rate (%) 16.1 25.5 33.5 21.4 22.0 14.0 13.5 14.7 13.9 20.6
Rota, rotavirus; Ag, antigen.
A decreasing pattern of positive tests was observed.
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rus, RotaShield®, was withdrawn due to an increasing risk of IS. 
This is thought to be based on a difference in the viral strain 
used in that vaccine; however, its mechanisms are not fully 
understood yet.27 Despite the fact that post-licensure studies 
showed no increased risk of IS after rotavirus vaccination, this 
matter is still the subject of debate. According to a recent study 
conducted in the United States, RotaTeq® was found to increase 
cases of IS by approximately 1.5 (95% CI, 0.2 to 3.2) per 100000 
recipients after one dose, although no significant increase in 
risk was shown after the second and third doses.28,29 In Mexico, 
the first dose of the rotavirus vaccine was associated with an 
increased risk of IS between 5.3 and 5.8 within seven days af-
ter vaccination. By contrast, in Brazil, a second dose of the 
vaccine increased the risk of IS by 1.9 to 2.6 within seven days 
after vaccination, while no increased risk of IS was seen after 
the first dose.16 In Australia, two studies conducted showed 
opposite results. One found an increased risk of IS after both 
pentavalent and monovalent vaccination.18 However, another 
showed no overall increased risk of IS after both types of vac-
cination.17
When we used CIFs, the rotavirus vaccine-associated IS rate 
at our facility was 31.63 times higher than that of the United 
States report. However, after taking into consideration the dif-
ference in the background incidence rate of IS between the 
two countries, the incidence rate was seven times higher in our 
hospital. However, one thing that needs to be considered here 
is that our data, which are from a single center study, are small-
er compared to the United States data. Also, given that our facil-
ity is a tertiary medical center, the number of patients diag-
nosed and treated for IS may be much higher than the number 
of patients who visit for the sole purpose of receiving vaccina-
tions. Nevertheless, when we compared the cases with the ex-
pected cases, there was no increased IS risk associated with 
pentavalent rotavirus vaccination during the window period 
of four weeks post-vaccination, compared to the background 
incidence rate. These factors could have contributed to such 
discrepancy. In fact, a decreasing tendency was observed. Also, 
a fewer number of patients tested positive for rotavirus anti-
gen overall. 
There are some limitations in this study. First, it was not 
based on nationwide data. Since the data were collected only 
in our hospital, the numbers of corresponding data were small. 
Despite the results that showed RotaTeq® does not increase 
the risk of IS, it is thought that the precision of the estimates was 
affected by the number of cases. Second, the incidence rate of 
natural IS in Korea is unknown. The trend of the incidence rate 
of IS in children below 12 months of age in our hospital showed 
a decreasing pattern, from 142 cases to 15 cases per 100000 chil-
dren during the observation period. This is quite low compared 
with 47 cases in United States,13 81 cases in Australia,30 28.9 in 
Singapore,31 19.70–47.83 in Thailand,32 and 38 in Switzerland.33 
There is one report from Jeonbuk Province in Korea showing 
236 cases per 100000 children below 12 months of age,22 alth-
ough nationwide data are needed to fully understand and in-
terpret the results of this study. Third, our data were collected 
by reviewing electronic medical records. There could have been 
some missing data regarding medical conditions that can fos-
ter IS. Rotavirus vaccination is not included currently in the NIP 
in Korea. This means that it is not covered by insurance as Ko-
rea has a National Health Insurance System. This makes it ex-
tremely difficult to assess rotavirus vaccination status of all 
children in the country. We are planning to expand our study 
by obtaining data from multiple centers and eventually from 
all of Korea. Lastly, this study only investigated the effects of a 
pentavalent vaccine. Our center uses RotaTeq only, and thus, 
we do not have any information on the effects of Rotarix®, 
which is a monovalent vaccine.
Many studies examining whether IS is associated with rota-
virus vaccination are being conducted, and no consensus has 
been reached yet. However, the fact that rotavirus-associated 
morbidity has decreased has been established in many coun-
tries is why we need to weigh the risks against benefits. 
Rotavirus vaccines are still not included in the Korean NIP. 
As mentioned previously, there are rare mortalities, but con-
siderable morbidities, still associated with rotavirus gastroen-
teritis. Rotavirus has strong infectivity and can spread to more 
than 50 children in one minute. To cover rotavirus vaccination 
within the NIP, stronger evidence regarding the safety and ef-
fectiveness of this vaccination is needed. Towards this, a large 
study should be conducted to determine the association be-
tween rotavirus vaccination and IS.
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